This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 22/7/1213    most recent 01.ATV.0000023228.90866.29v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tietge, U. J.F. Articles by Rader, D. J. Search for Related Content PubMed PubMed Citation Articles by Tietge, U. J.F. Articles by Rader, D. J. Related Collections Lipids Genetically altered mice Growth factors/cytokines Lipid and lipoprotein metabolism

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22:1213.)
© 2002 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Human Secretory Phospholipase A₂ Mediates Decreased Plasma Levels of HDL Cholesterol and ApoA-I in Response to Inflammation in Human ApoA-I Transgenic Mice

Uwe J.F. Tietge; Cyrille Maugeais; Sissel Lund-Katz; David Grass; Frederick C. deBeer; Daniel J. Rader

From the Department of Medicine (U.J.F.T., C.M., D.J.R.), University of Pennsylvania School of Medicine, and Children’s Hospital of Philadelphia (S.L.-K.), Philadelphia, Pa; Xenogen Corp (D.G.), Cranbury, NJ; and the University of Kentucky (F.C.dB.), Lexington.

Correspondence to Daniel J. Rader, MD, University of Pennsylvania Medical Center, 654 BRB II/III, 421 Curie Blvd, Philadelphia, PA 19104-6160. E-mail rader{at}mail.med.upenn.edu

Objective— Plasma levels of high density lipoprotein (HDL) cholesterol and apolipoprotein (apo)A-I are decreased in inflammatory states. Secretory phospholipase A₂ (sPLA₂), an acute-phase protein, may play a key role in the pathophysiology of this phenomenon.

Methods and Results— To investigate the effects of sPLA₂ on human-like HDL particles in vivo, we generated transgenic mice overexpressing human apoA-I and human sPLA₂ (apoA-I/sPLA₂ mice). Compared with apoA-I mice, apoA-I/sPLA₂ mice had significantly lower plasma levels of phospholipids, HDL cholesterol, and apoA-I (each P<0.01). HDL from apoA-I/sPLA₂ mice was significantly depleted in phospholipids and cholesteryl esters (each P<0.001) but was enriched in protein and triglycerides (each P<0.001). As assessed by gel filtration and nondenaturing gel electrophoresis, sPLA₂ overexpression in apoA-I mice resulted in a dramatic shift of the HDL particle size toward smaller particles. Furthermore, virtually all plasma sPLA₂ in apoA-I/sPLA₂ mice was found in association with the HDL fraction. The acute-phase response was induced in apoA-I/sPLA₂ double-transgenic and apoA-I single-transgenic mice by intraperitoneal lipopolysaccharide (LPS) injection. Plasma sPLA₂ was significantly increased after LPS injection in apoA-I/sPLA₂ mice. Twelve hours after LPS administration, plasma total cholesterol, HDL cholesterol, apoA-I, and phospholipids were unchanged in apoA-I transgenic control mice but had decreased significantly in the apoA-I/sPLA₂ mice (-57%, -62%, and -54%, -61%, respectively; each P<0.001). Both groups of mice had increased plasma levels of serum amyloid A (SAA) in response to LPS. To test the hypothesis that SAA may be an in vivo activator of sPLA₂, we specifically overexpressed SAA in apoA-I/sPLA₂ mice by means of liver-directed gene transfer. Despite high plasma levels of SAA, plasma lipid and lipoprotein profiles were not different than those in control mice.

Conclusions— These results in a mouse model of human-like HDL indicate that sPLA₂ expression significantly influences HDL particle size and composition and demonstrate that an induction of sPLA₂ is required for the decrease in plasma HDL cholesterol in response to inflammatory stimuli in mice and that this effect is independent of SAA.

Key Words: apolipoproteins • lipoproteins • inflammation • phospholipase • HDL

This article has been cited by other articles:

				N. Nijstad, H. Wiersma, T. Gautier, M. van der Giet, C. Maugeais, and U. J. F. Tietge Scavenger Receptor BI-mediated Selective Uptake Is Required for the Remodeling of High Density Lipoprotein by Endothelial Lipase J. Biol. Chem., March 6, 2009; 284(10): 6093 - 6100. [Abstract] [Full Text] [PDF]

				F. C. McGillicuddy, M. de la Llera Moya, C. C. Hinkle, M. R. Joshi, E. H. Chiquoine, J. T. Billheimer, G. H. Rothblat, and M. P. Reilly Inflammation Impairs Reverse Cholesterol Transport In Vivo Circulation, March 3, 2009; 119(8): 1135 - 1145. [Abstract] [Full Text] [PDF]

				U. J. F. Tietge, N. Nijstad, R. Havinga, J. F. W. Baller, F. H. van der Sluijs, V. W. Bloks, T. Gautier, and F. Kuipers Secretory phospholipase A2 increases SR-BI-mediated selective uptake from HDL but not biliary cholesterol secretion J. Lipid Res., March 1, 2008; 49(3): 563 - 571. [Abstract] [Full Text] [PDF]

				K. O. Badellino, M. L. Wolfe, M. P. Reilly, and D. J. Rader Endothelial Lipase Is Increased In Vivo by Inflammation in Humans Circulation, February 5, 2008; 117(5): 678 - 685. [Abstract] [Full Text] [PDF]

				A. Kontush and M. J. Chapman Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374. [Abstract] [Full Text] [PDF]

				U. J. F. Tietge, D. Pratico, T. Ding, C. D. Funk, R. B. Hildebrand, T. Van Berkel, and M. Van Eck Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress J. Lipid Res., August 1, 2005; 46(8): 1604 - 1614. [Abstract] [Full Text] [PDF]

				G. F. Lewis and D. J. Rader New Insights Into the Regulation of HDL Metabolism and Reverse Cholesterol Transport Circ. Res., June 24, 2005; 96(12): 1221 - 1232. [Abstract] [Full Text] [PDF]

				A. Chait, C. Y. Han, J. F. Oram, and J. W. Heinecke Thematic review series: The Immune System and Atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J. Lipid Res., March 1, 2005; 46(3): 389 - 403. [Abstract] [Full Text] [PDF]

				W. Khovidhunkit, M.-S. Kim, R. A. Memon, J. K. Shigenaga, A. H. Moser, K. R. Feingold, and C. Grunfeld Thematic review series: The Pathogenesis of Atherosclerosis. Effects of infection and inflammation on lipid and lipoprotein metabolism mechanisms and consequences to the host J. Lipid Res., July 1, 2004; 45(7): 1169 - 1196. [Abstract] [Full Text] [PDF]

				H. W.M Niessen, P. A.J Krijnen, C. A Visser, C. J.L.M Meijer, and C Erik Hack Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes? Cardiovasc Res, October 15, 2003; 60(1): 68 - 77. [Abstract] [Full Text] [PDF]

				Y. Zhang, I. Zanotti, M. P. Reilly, J. M. Glick, G. H. Rothblat, and D. J. Rader Overexpression of Apolipoprotein A-I Promotes Reverse Transport of Cholesterol From Macrophages to Feces In Vivo Circulation, August 12, 2003; 108(6): 661 - 663. [Abstract] [Full Text] [PDF]

				L. C. Hudgins, T. S. Parker, D. M. Levine, B. R. Gordon, S. D. Saal, X.-c. Jiang, C. E. Seidman, J. D. Tremaroli, J. Lai, and A. L. Rubin A single intravenous dose of endotoxin rapidly alters serum lipoproteins and lipid transfer proteins in normal volunteers J. Lipid Res., August 1, 2003; 44(8): 1489 - 1498. [Abstract] [Full Text] [PDF]

				U. J. F. Tietge, C. Maugeais, W. Cain, and D. J. Rader Acute inflammation increases selective uptake of HDL cholesteryl esters into adrenals of mice overexpressing human sPLA2 Am J Physiol Endocrinol Metab, August 1, 2003; 285(2): E403 - E411. [Abstract] [Full Text] [PDF]

				S. Rashid, D. K. Trinh, K. D. Uffelman, J. S. Cohn, D. J. Rader, and G. F. Lewis Expression of Human Hepatic Lipase in the Rabbit Model Preferentially Enhances the Clearance of Triglyceride-Enriched Versus Native High-Density Lipoprotein Apolipoprotein A-I Circulation, June 24, 2003; 107(24): 3066 - 3072. [Abstract] [Full Text] [PDF]

				P. Barter Effects of Inflammation on High-Density Lipoproteins Arterioscler. Thromb. Vasc. Biol., July 1, 2002; 22(7): 1062 - 1063. [Full Text] [PDF]